Double-stranded DNA at user-specified genomic locus

The entry refers not to a specific endogenous molecule, protein, or defined biological target, but to a general strategy of targeting double-stranded DNA (dsDNA) at a chosen genomic locus using guide RNA-directed genome editing tools such as CRISPR-Cas9 or CRISPR-Cas12. In this paradigm, a guide RNA (gRNA or sgRNA) is designed to be complementary to a specific dsDNA sequence within the genome, which enables programmable, site-specific recognition and cleavage by a Cas nuclease (e.g., Cas9 or Cas12a)[1][2][4][5][8]. The locus is chosen by the user and does not represent a unique or defined biological entity or "target" in the conventional sense (e.g., receptor, enzyme, transporter), but rather any DNA sequence amenable to editing. This is an abstract targeting framework rather than a molecular target. Thus, it is not considered a canonical therapeutic target, is not associated with a specific biomarker, disease role, or interacting drugs, and its description is primarily relevant in the context of genome-editing methodologies and applications.